FDA's KOMZIFTI Approval Signals Continued Flexibility on Single-Arm AML Trials

Kura Oncology's November 2025 accelerated approval of ziftomenib (KOMZIFTI) for relapsed/refractory AML with NPM1 mutation reinforces a regulatory posture that hematologic oncology teams have been tracking closely: FDA's sustained willingness to accept single-arm trial data with remission-based endpoints as the evidentiary foundation for approval in high-unmet-need settings. For regulatory affairs leads and CMC teams, that posture carries direct implications for how post-approval commitments and confirmatory trial obligations will be structured.

FDA granted approval based on Study KO-MEN-001 (NCT04067336), a single-arm, open-label, multicenter trial enrolling 112 adult patients with relapsed or refractory AML harboring an NPM1 mutation. The dataset pooled 20 patients from a Phase 1b cohort and 92 from a Phase 2 cohort, all receiving KOMZIFTI at 600 mg orally once daily. The primary endpoint was the combined rate of complete remission (CR) and complete remission with partial hematologic recovery (CRh). Secondary measures included duration of CR+CRh and rate of conversion to transfusion independence. Patients were enrolled across 42 sites in seven countries, including the United States, Canada, Belgium, France, Germany, Italy, and Spain, with 52 U.S. patients in the dataset.

The trial design reflects the practical constraints of studying a molecularly defined, heavily pretreated population. A randomized controlled arm is operationally difficult to power in NPM1-mutant relapsed/refractory AML, and FDA's acceptance of CR+CRh as a surrogate endpoint is consistent with its approach in comparable hematologic indications. QA and regulatory teams should note that accelerated approval under this framework typically triggers mandatory confirmatory trial requirements, and CMC functions will need to align process validation timelines and post-market surveillance protocols accordingly. The indication is also restricted to patients with no satisfactory alternative treatment options, a label qualifier that will require careful attention in promotional review and medical affairs planning.

KOMZIFTI is administered as an oral capsule at 600 mg once daily, with treatment continuing until disease progression or unacceptable toxicity. The prescribing information permits resumption of therapy following hematopoietic stem cell transplant, a clinically relevant provision for a patient population where HSCT remains a standard consolidation strategy. Plant heads and supply chain leads should factor the oral solid dosage form into GMP readiness planning, particularly given the multinational trial footprint that may inform commercial distribution expectations.

Source: FDA Drug Trials Snapshots for KOMZIFTI, published April 28, 2026, based on original approval data from November 13, 2025. Refer to the KOMZIFTI Prescribing Information for all approved conditions of use.